Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To evaluate efficacy and tolerability of Micardis® / MicardisPlus® under usual daily-practice prescribing conditions with a special emphasis on controlling morning blood pressure
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Essential hypertension |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Telmisartan | Drug |
| ||
| Telmisartan in combination with hydrochlorothiazide |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in morning blood pressure (BP) | Pre-dose, up to 6 months after start of treatment | |
| Changes in metabolic laboratory parameters | Pre-dose, up to 6 months after start of treatment | |
| Changes in morning blood pressure in patients with or without telemonitoring (TM) of BP | Pre-dose, up to 6 months after start of treatment | |
| Investigator assessment of efficacy in reducing morning hypertension on a 5-point rating scale | Up to 6 months after start of treatment | |
| Investigator assessment of effects on metabolism on a 3-point rating scale | Up to 6 months after start of treatment | |
| Investigator assessment of tolerability on a 5-point rating scale | Up to 6 months after start of treatment | |
| Number of patients with adverse events | Up to 6 months | |
| Changes in morning heart rate | Pre-dose, up to 6 months after start of treatment |
Not provided
Not provided
Inclusion Criteria:
- Age ≥ 18 years, insufficiently treated hypertension
Exclusion Criteria:
- Age < 18 years
Not provided
Not provided
Not provided
Outpatients with essential hypertension
Not provided
Not provided
Not provided
Not provided
| Drug |
|
| ID | Term |
|---|---|
| D006973 | Hypertension |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077333 | Telmisartan |
| D006852 | Hydrochlorothiazide |
| ID | Term |
|---|---|
| D001713 | Biphenyl Compounds |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D001562 | Benzimidazoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
| D002740 | Chlorothiazide |
| D001581 | Benzothiadiazines |
| D013449 | Sulfonamides |
| D013450 | Sulfones |
| D013457 | Sulfur Compounds |
| D049971 | Thiazides |
Not provided
Not provided